Bacterial, Parasitic and Zoonotic Diseases Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial College London, London, United Kingdom.
PLoS One. 2021 Dec 21;16(12):e0260722. doi: 10.1371/journal.pone.0260722. eCollection 2021.
The Geshiyaro project aims to break transmission of soil-transmitted helminths and schistosomiasis in the Wolaita Zone of Ethiopia through a combination of two interventions: behavior change communication (BCC) for increased water, sanitation and hygiene (WaSH) infrastructure use alongside preventive chemotherapy (PC) using albendazole (ALB) and praziquantel (PZQ), targeted to reach 90% treatment coverage. Coverage evaluation surveys (CES) were conducted post-treatment, and the resultant survey coverage was compared to reported administrative coverage. This provided a secondary confirmation of the Geshiyaro project coverages, and is used to monitor the success of each Mass Drug Administration (MDA) round.
A community-based cross-sectional study was conducted in 13 woredas (districts) of the Wolaita Zone. All eligible individuals from the selected households were invited for an interview. The study design, sample size, analysis and report writing were conducted according to the World Health Organization (WHO) CES guidelines for PC.
The study interviewed a total of 3,568 households and 18,875 individuals across 13 woredas in the Wolaita Zone. Overall, the survey coverage across all studied woredas was 81.5% (95% CI; 80.9-82.0%) for both ALB and PZQ. Reported administrative coverage across all studied woredas was higher than survey coverage, 92.7% and 91.2% for ALB and PZQ, respectively. A significant portion of individuals (17.6%) were not offered PC. The predominant reason for not achieving the target coverage of 90% was beneficiary absenteeism during MDA (6.6% ALB, 6.8% PZQ), followed by drug distributors failing to reach all households (4.7% ALB, 4.8% PZQ), and beneficiaries not informed of the program (1.3% ALB, 1.7% PZQ).
Programmatic actions will need to be taken during the next MDA campaign to achieve the targeted Geshiyaro project coverage threshold across data collection and program engagement. Adequate training and supervision on recording and reporting administrative coverage should be provided, alongside improved social mobilization of treated communities to increase participation, and strengthened institutional partnerships and communication.
Geshiyaro 项目旨在通过两种干预措施打破埃塞俄比亚沃莱塔地区土壤传播性蠕虫和血吸虫病的传播:通过行为改变沟通(BCC)增加对水、环境卫生和个人卫生(WASH)基础设施的使用,同时使用阿苯达唑(ALB)和吡喹酮(PZQ)进行预防性化疗(PC),目标是达到 90%的治疗覆盖率。治疗后进行了覆盖评估调查(CES),并将调查覆盖范围与报告的行政覆盖范围进行了比较。这为 Geshiyaro 项目的覆盖范围提供了二次确认,并用于监测每次大规模药物管理(MDA)回合的成功。
在沃莱塔地区的 13 个沃里达(区)进行了一项基于社区的横断面研究。从选定的家庭中邀请所有符合条件的个人进行访谈。该研究设计、样本量、分析和报告写作均根据世界卫生组织(WHO)针对 PC 的 CES 指南进行。
该研究共访谈了沃莱塔地区 13 个沃里达的 3568 户家庭和 18875 人。总体而言,在所研究的所有沃里达,ALB 和 PZQ 的调查覆盖率分别为 81.5%(95%CI;80.9-82.0%)。在所研究的所有沃里达,报告的行政覆盖率均高于调查覆盖率,分别为 ALB 和 PZQ 的 92.7%和 91.2%。相当一部分人(17.6%)未接受 PC。未达到 90%目标覆盖率的主要原因是在 MDA 期间受益人缺勤(ALB 为 6.6%,PZQ 为 6.8%),其次是药品分发人员未能覆盖所有家庭(ALB 为 4.7%,PZQ 为 4.8%),以及未通知受益人该计划(ALB 为 1.3%,PZQ 为 1.7%)。
在下一次 MDA 运动中,需要采取方案行动,以在数据收集和方案参与过程中达到 Geshiyaro 项目的目标覆盖阈值。应提供关于记录和报告行政覆盖范围的充分培训和监督,同时加强对已治疗社区的社会动员,以提高参与度,并加强机构伙伴关系和沟通。